A Phase 1 Study of HDM2017 in Advanced Solid Tumors

Summary

This is a phase I clinical study. All subjects are patients with advanced solid tumors. The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor efficacy of HDM2017 in patients with advanced malignant solid tumors.

Timeline

Start

2025-11-18

Primary completion

2026-12-31

Completion

2027-07-01

Drugs

Indications